Praxis Precision Medicines
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 days.
- Its last 3 Sell calls were actually followed by a +4% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +32.7% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 15.1% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -2,340.3% | Better than 2% |
| Net margin | -2,137.5% | Better than 2% |
| Return on equity | -45.8% | Better than 10% |
| Return on invested capital | -45.8% | Better than 6% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -20.1% | Better than 31% |
| 6-month return | -12.6% | Better than 36% |
| 12-month return (ex latest month) | 49.0% | Better than 83% |
| Distance below 52-week high | 23.5% | Better than 53% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 10.2x | Better than 94% |
| Debt to assets | 0.0% | Better than 99% |
| Interest coverage | -206.9x | Better than 4% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 91.7% | Better than 75% |
| Upside to average target | 142.4% | Better than 90% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 310.90
- Open
- 310.07
- Day range
- 298.54 - 314.15
- Avg price
- 304.90
- Volume
- 806.16K
- Turnover
- 245.80M
- Turnover ratei
- 3.34%
- Volume ratioi
- 1.36
- Amplitudei
- 5.02%
- 52-week rangei
- 167.32 - 392.70
Valuation
- P/Ei
- -22.29
- P/E (TTM)i
- -23.43
- P/Bi
- 6.67
- EPSi
- -13.48
- Book value / shi
- 45.06
- Net profit
- -376.79M
- Net assets
- 1.26B
Share structure
- Market cap
- 8.40B
- Float capi
- 7.24B
- Shares out
- 27.95M
- Float sharesi
- 24.11M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-10-16
23.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+11.79M net over the window
Short interest
- Shares short
- 4.21M
- % of floati
- 15.07%
- Days to coveri
- 8.69
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Praxis Precision Medicines (PRAX)?
Praxis Precision Medicines last traded at 300.43. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Praxis Precision Medicines's market cap?
About 8.40B.
What is the P/E ratio of Praxis Precision Medicines?
The trailing twelve-month P/E is -23.43. The Valuation tab shows it against the stock's own five-year range.
Does Praxis Precision Medicines pay a dividend?
Praxis Precision Medicines does not currently pay a regular dividend.
Is Praxis Precision Medicines a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 728.33, which implies 142.4% upside from the current price. This is not investment advice.
What is Praxis Precision Medicines's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Praxis Precision Medicines a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.
Praxis Precision Medicines discussion 0 comments